# Pearl Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pearl-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Redwood City, US
- Website: www.pearltherapeutics.com
- Total disclosed funding: $109M
- Latest round: Series D (Nov 13, 2012)
- Investors on record: 5

## About

Pearl Therapeutics, Inc. is a pharmaceutical company focused on the development of innovative therapeutic solutions that address critical respiratory diseases through advanced drug delivery technologies.Founded in 2006, Pearl Therapeutics is based in Redwood City, US, and specializes in developing inhaled medications for respiratory conditions. In June 2013, AstraZeneca acquired Pearl Therapeutics for an initial USD 560 mn, with potential additional payments based on development milestones.Pearl Therapeutics, Inc. is dedicated to innovating treatments for respiratory diseases, primarily developing inhalation products that improve patient outcomes through advanced drug delivery systems.Pearl Therapeutics, Inc. does not publicly disclose specific revenue figures, as it operates within the pharmaceutical sector under AstraZeneca's umbrella, which handles sales and partnerships for these products.Pearl Therapeutics plans to leverage its recent acquisition by AstraZeneca to enhance its pipeline of inhalation therapies. The acquisition, finalized on June 27, 2013, includes an initial USD 560 mn payment with additional performance-based incentives. Future initiatives may involve expanding into new therapeutic areas and refining existing products to improve market reach.

## Funding rounds

- Series D, Nov 13, 2012, $23M — 5AM Ventures, Clarus Ventures, New Leaf Venture Partners, Vatera Healthcare Partners
- Series C, Oct 19, 2010, $37M — 5AM Ventures, Clarus Ventures, New Leaf Venture Partners, Vatera Healthcare Partners
- Series C, Feb 1, 2010, $15M — 5AM Ventures, Clarus Ventures, New Leaf Venture Partners
- Series A, Jul 2, 2008, $18M — 5AM Ventures, Clarus Ventures, New Leaf Venture Partners, Nektar Therapeutics
- Series B, Sep 6, 2007, $16M — 5AM Ventures, Clarus Ventures, New Leaf Venture Partners

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series B, Series A, Series C, Series D
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B, Series A, Series C, Series D
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series A, Series C, Series D
- Nektar Therapeutics — Series A
- Vatera Healthcare Partners — Series C, Series D